Pharmacological treatments for methamphetamine addiction: current status and future directions

References

• Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings|SAMHSA [Internet]. 2014 [cited 2016 Aug 9]. Available from: http://store.samhsa.gov/product/Results-from-the-2013-National-Survey-on-Drug-Use-and-Health-Summary-of-National-Findings/SMA14-4863.
   Google Scholar
• Ho EL, Josephson SA, Lee HS, et al. Cerebrovascular complications of methamphetamine abuse. Neurocrit Care. 2009;10:295–305.
   PubMed Web of Science ®Google Scholar
• Won S, Hong RA, Shohet RV, et al. Methamphetamine-associated cardiomyopathy. Clin Cardiol. 2013;36:737–742.
   PubMed Web of Science ®Google Scholar
• Shetty V, Harrell L, Murphy DA, et al. Dental disease patterns in methamphetamine users: Findings in a large urban sample. J Am Dent Assoc 1939. 2015;146:875–885.
   PubMed Web of Science ®Google Scholar
• Callaghan RC, Cunningham JK, Sykes J, et al. Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 2012;120:35–40.
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179–187.
   PubMed Web of Science ®Google Scholar
• Forray A, Sofuoglu M. Future pharmacological treatments for substance use disorders. Br J Clin Pharmacol. 2014;77:382–400.
   PubMed Web of Science ®Google Scholar
• Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2014;143:11–21.
   PubMed Web of Science ®Google Scholar
• Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013;129:167–179.
   PubMed Web of Science ®Google Scholar
• Brensilver M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev. 2013;32:449–460.
   PubMed Web of Science ®Google Scholar
• Anderson AL, Li S-H, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015;150:170–174.
   PubMed Web of Science ®Google Scholar
• Colfax GN, Santos G, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68:1168–1175.
   PubMed Web of Science ®Google Scholar
• Galloway GP, Newmeyer J, Knapp T, et al. A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat. 1996;13:493–497.
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Huber A, Peck J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85:12–18.
   PubMed Web of Science ®Google Scholar
• Galloway G, Buscemi R, Coyle J, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011;89:276–282.
   PubMed Web of Science ®Google Scholar
• Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014;109:1489–1500.
   PubMed Web of Science ®Google Scholar
• Rezaei F, Emami M, Zahed S, et al. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. DARU J Pharm Sci [Internet]. 2015 [cited 2016 Apr 3]:23. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298048/
   Google Scholar
• Anderson AL, Li S-H, Biswas K, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012;120:135–141.
   PubMed Web of Science ®Google Scholar
• Ma JZ, Johnson BA, Yu E, et al. Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug Alcohol Depend. 2013;130:45–51.
   PubMed Web of Science ®Google Scholar
• Heinzerling KG, Shoptaw S, Peck JA, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85:177–184.
   PubMed Web of Science ®Google Scholar
• Coffin PO, Santos G-M, Das M, et al. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013;108:751–761.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol. 2010;20:823–828.
   PubMed Web of Science ®Google Scholar
• Mousavi SG, Sharbafchi MR, Salehi M, et al. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study. Arch Iran Med. 2015;18:28–33.
   PubMed Web of Science ®Google Scholar
• Chomchai C, Chomchai S. Global patterns of methamphetamine use. Curr Opin Psychiatry. 2015;28:269–274.
   PubMed Web of Science ®Google Scholar
• Barati M, Ahmadpanah M, Soltanian AR. Prevalence and factors associated with methamphetamine use among adult substance abusers. J Res Health Sci. 2014;14:221–226.
   PubMedGoogle Scholar
• Becker JB, Perry AN, Westenbroek C. Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis. Biol Sex Differ. 2012;3:14.
   PubMed Web of Science ®Google Scholar
• Korte JE, Hiott FB, Brady KT, et al. Distinctive characteristics of methamphetamine users presenting at public clinics: steep rise in South Carolina, United States, 2000-2005. Drug Alcohol Depend. 2011;115:9–15.
   PubMed Web of Science ®Google Scholar
• Hser Y-I, Evans E, Huang Y-C. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat. 2005;28:77–85.
   PubMed Web of Science ®Google Scholar
• Conway KP, Compton W, Stinson FS, et al. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the national epidemiologic survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67:247–258.
   PubMed Web of Science ®Google Scholar
• Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011;186:356–361.
   PubMed Web of Science ®Google Scholar
• Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab Brain Dis. 2014;29:351–357.
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Sewell RA. Norepinephrine and stimulant addiction. Addict Biol. 2009;14:119–129.
   PubMed Web of Science ®Google Scholar
• Müller CP, Homberg JR. The role of serotonin in drug use and addiction. Behav Brain Res. 2015;277:146–192.
   PubMed Web of Science ®Google Scholar
• Hondebrink L, Meulenbelt J, van Kleef RGDM, et al. Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse. Neurotoxicology. 2011;32:823–827.
   PubMed Web of Science ®Google Scholar
• Loweth JA, Tseng KY, Wolf ME. Adaptations in AMPA receptor transmission in the nucleus accumbens contributing to incubation of cocaine craving. Neuropharmacology. 2014;76(Pt B):287–300.
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–773.
   PubMed Web of Science ®Google Scholar
• Scofield MD, Heinsbroek JA, Gipson CD, et al. The nucleus accumbens: mechanisms of addiction across drug classes reflect the importance of glutamate homeostasis. Pharmacol Rev. 2016;68:816–871.
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Mooney M. Cholinergic functioning in stimulant addiction: implications for medications development. CNS Drugs. 2009;23:939–952.
   PubMed Web of Science ®Google Scholar
• Koob GF. The dark side of emotion: the addiction perspective. Eur J Pharmacol. 2015;753:73–87.
   PubMed Web of Science ®Google Scholar
• Loftis JM, Janowsky A. Neuroimmune basis of methamphetamine toxicity. Int Rev Neurobiol. 2014;118:165–197.
   PubMed Web of Science ®Google Scholar
• Abdul Muneer PM, Alikunju S, Szlachetka AM, et al. Methamphetamine inhibits the glucose uptake by human neurons and astrocytes: stabilization by acetyl-L-carnitine. Plos One. 2011;6:e19258.
   PubMed Web of Science ®Google Scholar
• Kousik SM, Napier TC, Carvey PM. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Front Pharmacol. 2012;3:121.
   PubMed Web of Science ®Google Scholar
• Bachtell R, Hutchinson MR, Wang X, et al. Targeting the toll of drug abuse: the translational potential of toll-like receptor 4. CNS Neurol Disord Drug Targets. 2015;14:692–699.
   PubMed Web of Science ®Google Scholar
• Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology. 1998;18:135–174.
   PubMed Web of Science ®Google Scholar
• Georgiou P, Zanos P, Garcia-Carmona J-A, et al. Methamphetamine abstinence induces changes in μ-opioid receptor, oxytocin and CRF systems: association with an anxiogenic phenotype. Neuropharmacology. 2016;105:520–532.
   PubMed Web of Science ®Google Scholar
• Mishra D, Pena-Bravo JI, Leong K-C, et al. Methamphetamine self-administration modulates glutamate neurophysiology. Brain Struct Funct. 2016;1-9. doi:10.1007/s00429-016-1322-x
   PubMedGoogle Scholar
• Shen H, Mohammad A, Ramroop J, et al. A stress steroid triggers anxiety via increased expression of α4βδ GABAA receptors in methamphetamine dependence. Neuroscience. 2013;254:452–475.
   PubMed Web of Science ®Google Scholar
• Clark KH, Wiley CA, Bradberry CW. Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res. 2013;23:174–188.
   PubMed Web of Science ®Google Scholar
• Gavrilin MA, Mathes LE, Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol. 2002;8:240–249.
   PubMed Web of Science ®Google Scholar
• Liang H, Wang X, Chen H, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol. 2008;172:1617–1624.
   PubMed Web of Science ®Google Scholar
• Weber E, Morgan EE, Iudicello JE, et al. Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol. 2013;19:65–74.
   PubMed Web of Science ®Google Scholar
• Hart CL, Marvin CB, Silver R, et al. Is cognitive functioning impaired in methamphetamine users? a critical review. Neuropsychopharmacology. 2012;37:586–608.
   PubMed Web of Science ®Google Scholar
• Dean AC, Groman SM, Morales AM, et al. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology. 2013;38:259–274.
   PubMed Web of Science ®Google Scholar
• Darke S, Farrell M. Which medications are suitable for agonist drug maintenance?. Addiction. 2016;111:767–774.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Tomasi D, Wang G-J, et al. Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. Mol Psychiatry. 2014;19:1037–1043.
   PubMed Web of Science ®Google Scholar
• Hutson PH, Pennick M, Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014;87:41–50.
   PubMed Web of Science ®Google Scholar
• Barr AM, Markou A, Phillips AG. A “crash” course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci. 2002;23:475–482.
   PubMed Web of Science ®Google Scholar
• Newton TF, Kalechstein AD, Duran S, et al. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004;13:248–255.
   PubMed Web of Science ®Google Scholar
• Baker DA, McFarland K, Lake RW, et al. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci. 2003;1003:349–351.
   PubMed Web of Science ®Google Scholar
• Deepmala D, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015;55:294–321.
   PubMed Web of Science ®Google Scholar
• Weinshenker D, Schroeder JP. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacol. 2007;32:1433–1451.
   PubMed Web of Science ®Google Scholar
• Lingham T, Perlanski E, Grupp LA. Angiotensin converting enzyme inhibitors reduce alcohol consumption: some possible mechanisms and important conditions for its therapeutic use. Alcohol Clin Exp Res. 1990;14:92–99.
   PubMed Web of Science ®Google Scholar
• Noble F, Lenoir M, Marie N. The opioid receptors as targets for drug abuse medication. Br J Pharmacol. 2015;172:3964–3979.
   PubMed Web of Science ®Google Scholar
• Pal R, Mendelson JE, Flower K, et al. Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study. J Addict Med. 2015;9:130–135.
   PubMed Web of Science ®Google Scholar
• Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015;40:2347–2356.
   PubMed Web of Science ®Google Scholar
• Salehi M, Emadossadat A, Kheirabadi GR, et al. The effect of buprenorphine on methamphetamine cravings. J Clin Psychopharmacol. 2015;35:724–727.
   PubMed Web of Science ®Google Scholar
• Lacagnina MJ, Rivera PD, Bilbo SD. Glial and neuroimmune mechanisms as critical modulators of drug use and abuse. Neuropsychopharmacology. 2017 Jan;42(1):156–177. doi:10.1038/npp.2016.121.
   PubMed Web of Science ®Google Scholar
• Thomas DM, Walker PD, Benjamins JA, et al. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther. 2004;311:1–7.
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Mooney M, Kosten T, et al. Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacol (Berl). 2011;213:61–68.
   PubMed Web of Science ®Google Scholar
• Worley MJ, Heinzerling KG, Roche DJO, et al. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug Alcohol Depend. 2016;162:245–250.
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, DeVito EE, Waters AJ, et al. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013;64:452–463.
   PubMed Web of Science ®Google Scholar
• Bates ME, Pawlak AP, Tonigan JS, et al. Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychol Addict Behav J Soc Psychol Addict Behav. 2006;20:241–253.
   PubMed Web of Science ®Google Scholar
• Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addict Abingdon Engl. 2010;105:38–48.
   PubMed Web of Science ®Google Scholar
• Verrico CD, Mahoney JJ, Thompson-Lake DGY, et al. Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2014;17:223–233.
   PubMed Web of Science ®Google Scholar
• Kim C-H, Hahn MK, Joung Y, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A. 2006;103:19164–19169.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699–711.
   PubMed Web of Science ®Google Scholar
• Swanson CJ, Perry KW, Koch-Krueger S, et al. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology. 2006;50:755–760.
   PubMed Web of Science ®Google Scholar
• Mereu M, Bonci A, Newman AH, et al. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacol (Berl). 2013;229:415–434.
   PubMed Web of Science ®Google Scholar
• Wignall ND, Brown ES. Citicoline in addictive disorders: a review of the literature. Am J Drug Alcohol Abuse. 2014;40:262–268.
   PubMed Web of Science ®Google Scholar
• Ohia-Nwoko O, Kosten TA, Haile CN. Animal models and the development of vaccines to treat substance use disorders. Int Rev Neurobiol. 2016;126:263–291.
   PubMed Web of Science ®Google Scholar
• Sarnyai Z, Kovács GL. Oxytocin in learning and addiction: From early discoveries to the present. Pharmacol Biochem Behav. 2014;119:3–9.
   PubMed Web of Science ®Google Scholar
• Baracz SJ, Cornish JL. The neurocircuitry involved in oxytocin modulation of methamphetamine addiction. Front Neuroendocrinol [Internet]. [cited 2016 Oct 1]. Available from: http://www.sciencedirect.com/science/article/pii/S0091302216300346
   Web of Science ®Google Scholar
• Scott JC, Woods SP, Matt GE, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007;17:275–297.
   PubMed Web of Science ®Google Scholar
• Simon SL, Dean AC, Cordova X, et al. Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs. 2010;71:335–344.
   PubMed Web of Science ®Google Scholar